Adverse events of inactivated COVID-19 vaccine in HIV-infected adults

Wu, Songjie; Zhang, Yubin; Ming, Fangzhao; Zou, Shi; Wu, Mengmeng; Guo, Wei; Tang, Weiming; Liang, Ke

doi:10.1186/s12981-021-00416-1

Cited by 9 publications

(26 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were also found in inactivated COVID-19 vaccine ( 10 ). Our former study also showed no serious adverse events for COVID-19 vaccination were observed among PLWH in China ( 11 ). Above evidence had proved that PLWH could benefit from COVID-19 vaccination.…”

Section: Introductionmentioning

confidence: 69%

“…The national technical guideline for COVID-19 vaccination in China encourages PLWH to take up inactivated vaccines or recombinant subunit vaccines ( 38 ). Several studies have reported that the PLWH has a comparable immune response to COVID-19 vaccines and there are no serious adverse events after COVID-19 vaccination ( 11 , 39 ). It is essential to design and develop health education programs to improve their perceptions and confidence in COVID-19 vaccines to improve COVID-19 vaccination coverage.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

COVID-19 Vaccination Willingness Among People Living With HIV in Wuhan, China

Ming

Xing

et al. 2022

Front. Public Health

Self Cite

View full text Add to dashboard Cite

Vaccination is essential to controlling the pandemic of coronavirus disease 2019 (COVID-19). People living with HIV (PLWH) were considered more vulnerable to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection compared with the general population. Therefore, it is urgent to protect PLWH from SARS-CoV-2 infection. For PLWH, vaccine hesitancy could be more common and may compromise vaccine coverage. Our study aimed to investigate the willingness to receive the COVID-19 vaccination among PLWH and associated factors. A cross-sectional online survey was performed among PLWH and the general population from 4 April to 18 April 2021 in Wuhan, China. The multivariable logistic regression was used to analyze associated factors for COVID-19 vaccination willingness among PLWH. A total of 556 PLWH and 570 individuals from the general population were enrolled. The COVID-19 vaccine willingness among PLWH was 60.8%, which was relatively lower than that in the general population (80.9%) (P < 0.001). The results of multivariable analysis indicated that PLWH with comorbidities (OR = 2.07, 95% CI: 1.25–3.45), those who had idea about PLWH would be more serious if they were infected with SARS-CoV-2 (OR = 1.67, 95% CI: 1.11–2.51) and those who thought their antiretroviral therapy (ART) would be affected by COVID-19 epidemic (OR = 2.04, 95% CI: 1.22–3.42) had higher willingness to receive COVID-19 vaccination. PLWH who had a monthly income over 5,000 RMB (OR = 0.64, 95% CI: 0.45–0.92) and had a sex orientation as non-homosexual (OR = 0.67, 95% CI: 0.47–0.96) were associated with lower willingness for COVID-19 vaccination. Our findings showed that the PLWH had a lower willingness for COVID-19 vaccination compared with the general population in Wuhan. Targeted interventions such as health education should be conducted to increase the willingness for COVID-19 vaccination among PLWH, thus enhancing COVID-19 vaccine uptake among PLWH.

show abstract

Section: Introductionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 98%

COVID-19 Vaccination Willingness Among People Living With HIV in Wuhan, China

Ming

Xing

et al. 2022

Front. Public Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our current knowledge on COVID-19 vaccination in PLWHA was based on the findings from trials involving stable HIV patients that suggest the safety, tolerability, and immunogenicity of COVID-19 vaccines [ 5 – 8 ]. This is also emphasized by the recommendations of the WHO and CDC for COVID-19 vacci-nation in PLWHA [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

“…Other studies reported that inactivated COVID-19 vaccine showed safety in PLWHA who received ART but a poor immunological response was observed in those with CD4+ count <350 cells/µl [ 7 ]. Furthermore, there are also no data reporting that these COVID-19 vaccines are inefficacious and unsafe or interfere with ART [ 5 – 8 ]. Here, we report 2 cases of young men with previously unknown HIV status whose neurological symptoms emerged and worsened progressively after receiving the first dose of vaccine against SARS-CoV-2.…”

Section: Introductionmentioning

confidence: 99%

Progressive Worsening of Neurological Manifestations in HIV-Associated Opportunistic Central Nervous System (CNS) Infection Patients After COVID-19 Vaccinations: A Possible Co-Incidence Causality

et al. 2022

View full text Add to dashboard Cite

“…These studies comprised one cross-sectional study, 16 one case-control study 17 and 20 cohort studies 12,13,[18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] (15 prospective cohort studies, 13,[18][19][20][21][22][23][24][25][26][27]29,31,32,35 three retrospective cohort studies 12,28,34 and one nonrandomized cohort study 33 ). These 22 studies were conducted in different regions, including Asia, 13,[16][17][18]21,23,32,33,35 Europe, 12,…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Safety and Immunogenicity of SARS-CoV-2 Vaccines in People Living With HIV (PLWH): A Systematic Review and Meta-analysis of Real-World Studies

Fan,

Zhao,

et al. 2023

Infect Microb Dis

View full text Add to dashboard Cite

The safety and immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in people living with HIV (PLWH) in real world studies remain controversial. Thus, we conducted a comprehensive systematic review and meta-analysis to address this issue. Data search were conducted from PubMed, Web of science, and Embase. Adverse events following vaccination, the risk ratio (RR) of SARS-CoV-2-specific IgG seroconversion, and the level of anti-SARS-CoV-2 neutralizing antibodies were compared between the PLWH group and a healthy control group. A total of 10,582 PLWH from 22 studies were included. In our analysis, the incidence of local or systemic adverse events after the first SARS-CoV-2 vaccine dose was not statistically different between PLWH and healthy controls. However, there was a statistical difference after the second dose (RR = 0.83, 95% CI: 0.71 – 0.98). The seroconversion rate of SARS-CoV-2 IgG antibodies in PLWH was significantly lower than that in the healthy control group (RR = 0.94, 95% CI: 0.89-0.98; I2 = 80%, P < 0.01). The anti-SARS-CoV-2 neutralizing antibody titers in PLWH after full immunization were also significantly lower than that in the healthy control group (RR = 0.91, 95% CI: 0.85-0.98; I2 = 81%, P < 0.01). The safety and tolerance of COVID-19 vaccines in PLWH are acceptable. However, their immunogenicity may be impaired to a certain extent, characterized by a lower IgG seroconversion rate and neutralizing antibody titers compared with healthy individuals. These findings should provide guidance for optimizing future COVID-19 vaccination strategies among PLWH.

show abstract

Adverse events of inactivated COVID-19 vaccine in HIV-infected adults

Cited by 9 publications

References 6 publications

COVID-19 Vaccination Willingness Among People Living With HIV in Wuhan, China

COVID-19 Vaccination Willingness Among People Living With HIV in Wuhan, China

Progressive Worsening of Neurological Manifestations in HIV-Associated Opportunistic Central Nervous System (CNS) Infection Patients After COVID-19 Vaccinations: A Possible Co-Incidence Causality

Safety and Immunogenicity of SARS-CoV-2 Vaccines in People Living With HIV (PLWH): A Systematic Review and Meta-analysis of Real-World Studies

Contact Info

Product

Resources

About